북미 및 유럽의 감염증 분자진단 시장 규모, 점유율 및 동향 분석 보고서 : 용도별, 검사 카테고리별, 고객 유형별 및 부문별 예측(2026-2033년)

North America & Europe Infectious Disease Molecular Diagnostics Market Summary

The North America & Europe infectious disease molecular diagnostics market size was estimated at USD 6.09 billion in 2025 and is projected to reach USD 10.77 billion by 2033, growing at a CAGR of 7.44% from 2026 to 2033. The market is driven by the increasing burden of infectious diseases, including respiratory infections, HIV, and hospital-acquired infections, which is accelerating demand for rapid and highly accurate diagnostic solutions.

Growth is further supported by continuous advancements in molecular technologies such as PCR, multiplex assays, and next-generation sequencing, along with strong healthcare infrastructure and government investments in disease surveillance and early detection systems.

North America & Europe Infectious Disease Molecular Diagnostics Market Report Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the North America & Europe infectious disease molecular diagnostics market on the basis of test category, application customer type, setting-based, throughput, algorithm-based, region:

• Application Outlook (Revenue, USD Million, 2021 - 2033)
• Gastrointestinal Infections
  • Syndromic Test
  • Targeted Test
  • Point of Care Molecular Diagnostics
• Respiratory Infection Testing
  • Syndromic Test
  • Targeted Test
  • Point of Care Molecular Diagnostics
• Hospital-Acquired Infections (HAIs)
  • Disease Type
  • Methicillin-Resistant Staphylococcus Aureus (MRSA)
  • Clostridioides difficile Infection (CDI)
  • Carbapenem-Resistant Enterobacteriaceae (CRE)
  • Vancomycin-Resistant Enterococci (VRE)
  • Other Nosocomial Pathogens
  • Test Category
  • Syndromic Test
  • Targeted Test
  • Point of Care Molecular Diagnostics
• Bloodstream Infections
  • Syndromic Test
  • Targeted Test
  • Point of Care Molecular Diagnostics
• Meningitis / CNS Infections
• Vector-Borne Infections
  • Disease Type
  • Dengue
  • Zika
  • Lyme Disease
  • West Nile Virus
  • Chikungunya
  • Other Vector-Borne Infections
• Test Category Outlook (Revenue, USD Million, 2021 - 2033)
• Syndromic Test
• Targeted Test
• Point of Care Molecular Diagnostics
• Customer Type Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital Laboratories
• Reference Laboratories
• Academic Centers
• Regional Hospitals
• Children's Hospital
• Other
• Setting-Based Outlook (Revenue, USD Million, 2021 - 2033)
• Central Laboratories
• Near-Patient Settings
• Throughput Outlook (Revenue, USD Million, 2021 - 2033)
• Low-volume Laboratories
• Mid-volume Laboratories
• High-volume Laboratories
• Algorithm-based Outlook (Revenue, USD Million, 2021 - 2033)
• Frontline Screening
• Reflex/Algorithm-driven Testing
• Syndromic Testing
• Targeted Confirmation
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Application
  • 1.2.2. Test Category
  • 1.2.3. Customer Type
  • 1.2.4. Setting-based
  • 1.2.5. Throughput
  • 1.2.6. Algorithm-based
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. North America and Europe Infectious Disease Molecular Diagnostics Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising burden of infectious diseases & antimicrobial resistance (amr)
    • 3.2.1.2. Rapid adoption of syndromic molecular testing
    • 3.2.1.3. Shift toward decentralized & near-patient testing
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. High cost of molecular testing & infrastructure dependence
    • 3.2.2.2. Stringent and evolving regulatory requirements (FDA & IVDR impact)
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. North America and Europe Infectious Disease Molecular Diagnostics Market: Application Business Analysis

• 4.1. Application Market Share, 2025 & 2033
• 4.2. Application Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Million)
• 4.4. Gastrointestinal Infections
  • 4.4.1. Gastrointestinal Infections Market, 2021 - 2033 (USD Million)
    • 4.4.1.1. Test Category
      • 4.4.1.1.1. Test Category Market, 2021 - 2033 (USD Million)
        • 4.4.1.1.1.1. Syndromic Test
          • 4.4.1.1.1.1.1. Syndromic Test Market, 2021 - 2033 (USD Million)
        • 4.4.1.1.1.2. Targeted Test
          • 4.4.1.1.1.2.1. Targeted Test Market, 2021 - 2033 (USD Million)
        • 4.4.1.1.1.3. Point of Care Molecular Diagnostics
          • 4.4.1.1.1.3.1. Point of Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
• 4.5. Respiratory Infection Testing
  • 4.5.1. Respiratory Infection Testing Market, 2021 - 2033 (USD Million)
    • 4.5.1.1. Test Category
      • 4.5.1.1.1. Test Category Market, 2021 - 2033 (USD Million)
        • 4.5.1.1.1.1. Syndromic Test
          • 4.5.1.1.1.1.1. Syndromic Test Market, 2021 - 2033 (USD Million)
        • 4.5.1.1.1.2. Targeted Test
          • 4.5.1.1.1.2.1. Targeted Test Market, 2021 - 2033 (USD Million)
        • 4.5.1.1.1.3. Point of Care Molecular Diagnostics
          • 4.5.1.1.1.3.1. Point of Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
• 4.6. Hospital-Acquired Infections (HAIs)
  • 4.6.1. Hospital-Acquired Infections (HAIs) Market, 2021 - 2033 (USD Million)
    • 4.6.1.1. Disease Type
      • 4.6.1.1.1. Disease Type Market, 2021 - 2033 (USD Million)
        • 4.6.1.1.1.1. Methicillin-Resistant Staphylococcus Aureus (MRSA)
          • 4.6.1.1.1.1.1. Methicillin-Resistant Staphylococcus Aureus (MRSA) Market, 2021 - 2033 (USD Million)
        • 4.6.1.1.1.2. Clostridioides Difficile Infection (CDI)
          • 4.6.1.1.1.2.1. Clostridioides difficile Infection (CDI) Market, 2021 - 2033 (USD Million)
        • 4.6.1.1.1.3. Carbapenem-Resistant Enterobacteriaceae (CRE)
          • 4.6.1.1.1.3.1. Carbapenem-Resistant Enterobacteriaceae (CRE) Market, 2021 - 2033 (USD Million)
        • 4.6.1.1.1.4. Vancomycin-Resistant Enterococci (VRE)
          • 4.6.1.1.1.4.1. Vancomycin-Resistant Enterococci (VRE) Market, 2021 - 2033 (USD Million)
        • 4.6.1.1.1.5. Other Nosocomial Pathogens
          • 4.6.1.1.1.5.1. Other Nosocomial Pathogens Market, 2021 - 2033 (USD Million)
    • 4.6.1.2. Test Category
      • 4.6.1.2.1. Test Category Market, 2021 - 2033 (USD Million)
        • 4.6.1.2.1.1. Syndromic Test
          • 4.6.1.2.1.1.1. Syndromic Test Market, 2021 - 2033 (USD Million)
        • 4.6.1.2.1.2. Targeted Test
          • 4.6.1.2.1.2.1. Targeted Test Market, 2021 - 2033 (USD Million)
        • 4.6.1.2.1.3. Point of Care Molecular Diagnostics
          • 4.6.1.2.1.3.1. Point of Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
• 4.7. Bloodstream Infections
  • 4.7.1. Bloodstream Infections Market, 2021 - 2033 (USD Million)
    • 4.7.1.1. Test Category
      • 4.7.1.1.1. Test Category Market, 2021 - 2033 (USD Million)
        • 4.7.1.1.1.1. Syndromic Test
          • 4.7.1.1.1.1.1. Syndromic Test Market, 2021 - 2033 (USD Million)
        • 4.7.1.1.1.2. Targeted Test
          • 4.7.1.1.1.2.1. Targeted Test Market, 2021 - 2033 (USD Million)
        • 4.7.1.1.1.3. Point of Care Molecular Diagnostics
          • 4.7.1.1.1.3.1. Point of Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)
• 4.8. Meningitis / CNS Infections
  • 4.8.1. Meningitis / CNS Infections Market, 2021 - 2033 (USD Million)
• 4.9. Vector-Borne Infections
  • 4.9.1. Vector-Borne Infections Market, 2021 - 2033 (USD Million)
    • 4.9.1.1. Disease Type
      • 4.9.1.1.1. Disease Type Market, 2021 - 2033 (USD Million)
        • 4.9.1.1.1.1. Dengue
          • 4.9.1.1.1.1.1. Dengue Market, 2021 - 2033 (USD Million)
        • 4.9.1.1.1.2. Zika
          • 4.9.1.1.1.2.1. Zika Market, 2021 - 2033 (USD Million)
        • 4.9.1.1.1.3. Lyme Disease
          • 4.9.1.1.1.3.1. Lyme Disease Market, 2021 - 2033 (USD Million)
        • 4.9.1.1.1.4. West Nile Virus
          • 4.9.1.1.1.4.1. West Nile Virus Market, 2021 - 2033 (USD Million)
        • 4.9.1.1.1.5. Chikungunya
          • 4.9.1.1.1.5.1. Chikungunya Market, 2021 - 2033 (USD Million)
        • 4.9.1.1.1.6. Other Vector-Borne Infections
          • 4.9.1.1.1.6.1. Other Vector-Borne Infections Market, 2021 - 2033 (USD Million)

Chapter 5. North America and Europe Infectious Disease Molecular Diagnostics Market: Test Category Business Analysis

• 5.1. Test Type Market Share, 2025 & 2033
• 5.2. Test Type Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Test Type, 2021 to 2033 (USD Million)
• 5.4. Syndromic Testing
  • 5.4.1. Syndromic Testing Market, 2021 - 2033 (USD Million)
• 5.5. Targeted Test
  • 5.5.1. Targeted In-Lab Testing Market, 2021 - 2033 (USD Million)
• 5.6. Point of Care Molecular Diagnostics
  • 5.6.1. Point of Care Molecular Diagnostics Market, 2021 - 2033 (USD Million)

Chapter 6. North America and Europe Infectious Disease Molecular Diagnostics Market: Customer Type Analysis

• 6.1. Customer Type Movement Analysis
• 6.2. Market Estimates & Forecast, by Customer Type (USD Million)
• 6.3. Hospital Laboratories
  • 6.3.1. Hospital Laboratories Market, 2021 - 2033 (USD Million)
• 6.4. Reference Laboratories
  • 6.4.1. Reference Laboratories Market, 2021 - 2033 (USD Million)
• 6.5. Academic Centers
  • 6.5.1. Academic Centers Market, 2021 - 2033 (USD Million)
• 6.6. Regional Hospitals
  • 6.6.1. Regional Hospitals Market, 2021 - 2033 (USD Million)
• 6.7. Children's Hospital
  • 6.7.1. Children's Hospital Market, 2021 - 2033 (USD Million)
• 6.8. Others
  • 6.8.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. North America and Europe Infectious Disease Molecular Diagnostics Market Setting-Based Analysis

• 7.1. Setting-Based Movement Analysis
• 7.2. Market Estimates & Forecast, by Setting-Based (USD Million)
• 7.3. Central Laboratories
  • 7.3.1. Central Laboratories Market, 2021 - 2033 (USD Million)
• 7.4. Near-Patient Settings
  • 7.4.1. Near-Patient Settings Market, 2021 - 2033 (USD Million)

Chapter 8. North America and Europe Infectious Disease Molecular Diagnostics Market: Throughput Analysis

• 8.1. Throughput Movement Analysis
• 8.2. Market Estimates & Forecast, by Throughput (USD Million)
• 8.3. Low-Volume Laboratories
  • 8.3.1. Low-Volume Laboratories Market, 2021 - 2033 (USD Million)
• 8.4. Mid-Volume Laboratories
  • 8.4.1. Mid-Volume Laboratories Market, 2021 - 2033 (USD Million)
• 8.5. High-Volume Laboratories
  • 8.5.1. High-Volume Laboratories Market, 2021 - 2033 (USD Million)

Chapter 9. North America and Europe Infectious Disease Molecular Diagnostics Market Algorithm-Based Analysis

• 9.1. Algorithm-Based Movement Analysis
• 9.2. Market Estimates & Forecast, by Algorithm-Based (USD Million)
• 9.3. Frontline Screening
  • 9.3.1. Frontline Screening Market, 2021 - 2033 (USD Million)
• 9.4. Reflex/Algorithm-Driven Testing
  • 9.4.1. Reflex/Algorithm-Driven Testing Market, 2021 - 2033 (USD Million)
• 9.5. Syndromic Testing (Algorithm-Based)
  • 9.5.1. Syndromic Testing (Algorithm-Based) Market, 2021 - 2033 (USD Million)
• 9.6. Targeted Confirmation
  • 9.6.1. Targeted Confirmation Market, 2021 - 2033 (USD Million)

Chapter 10. North America and Europe Infectious Disease Molecular Diagnostics Market: Regional Estimates & Trend Analysis

• 10.1. Regional Market Share Analysis, 2025 & 2033
• 10.2. Regional Market Dashboard
• 10.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 10.4. North America
  • 10.4.1. North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Million)
  • 10.4.2. U.S.
    • 10.4.2.1. Key Country Dynamics
    • 10.4.2.2. Target Disease Prevalence
    • 10.4.2.3. Regulatory Framework
    • 10.4.2.4. Reimbursement Framework
    • 10.4.2.5. U.S. North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.4.3. Canada
    • 10.4.3.1. Key Country Dynamics
    • 10.4.3.2. Target Disease Prevalence
    • 10.4.3.3. Regulatory Framework
    • 10.4.3.4. Reimbursement Framework
    • 10.4.3.5. Canada North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.4.4. Mexico
    • 10.4.4.1. Key Country Dynamics
    • 10.4.4.2. Target Disease Prevalence
    • 10.4.4.3. Regulatory Framework
    • 10.4.4.4. Reimbursement Framework
    • 10.4.4.5. Mexico North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 10.5. Europe
  • 10.5.1. Europe North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.5.2. UK
    • 10.5.2.1. Key Country Dynamics
    • 10.5.2.2. Target Disease Prevalence
    • 10.5.2.3. Regulatory Framework
    • 10.5.2.4. Reimbursement Framework
    • 10.5.2.5. Uk North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.5.3. Germany
    • 10.5.3.1. Key Country Dynamics
    • 10.5.3.2. Target Disease Prevalence
    • 10.5.3.3. Regulatory Framework
    • 10.5.3.4. Reimbursement Framework
    • 10.5.3.5. Germany North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.5.4. France
    • 10.5.4.1. Key Country Dynamics
    • 10.5.4.2. Target Disease Prevalence
    • 10.5.4.3. Regulatory Framework
    • 10.5.4.4. Reimbursement Framework
    • 10.5.4.5. France North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.5.5. Italy
    • 10.5.5.1. Key Country Dynamics
    • 10.5.5.2. Target Disease Prevalence
    • 10.5.5.3. Regulatory Framework
    • 10.5.5.4. Reimbursement Framework
    • 10.5.5.5. Italy North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.5.6. Spain
    • 10.5.6.1. Key Country Dynamics
    • 10.5.6.2. Target Disease Prevalence
    • 10.5.6.3. Regulatory Framework
    • 10.5.6.4. Reimbursement Framework
    • 10.5.6.5. Spain North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.5.7. Denmark
    • 10.5.7.1. Key Country Dynamics
    • 10.5.7.2. Target Disease Prevalence
    • 10.5.7.3. Regulatory Framework
    • 10.5.7.4. Reimbursement Framework
    • 10.5.7.5. Denmark North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.5.8. Sweden
    • 10.5.8.1. Key Country Dynamics
    • 10.5.8.2. Target Disease Prevalence
    • 10.5.8.3. Regulatory Framework
    • 10.5.8.4. Reimbursement Framework
    • 10.5.8.5. Sweden North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 10.5.9. Norway
    • 10.5.9.1. Key Country Dynamics
    • 10.5.9.2. Target Disease Prevalence
    • 10.5.9.3. Regulatory Framework
    • 10.5.9.4. Reimbursement Framework
    • 10.5.9.5. Norway North America and Europe Infectious Disease Molecular Diagnostics Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 11. Competitive Landscape

• 11.1. Participant Overview
• 11.2. Company Market Position Analysis
• 11.3. Company Categorization
• 11.4. Strategy Mapping
• 11.5. Company Profiles/Listing
  • 11.5.1. BD
    • 11.5.1.1. Overview
    • 11.5.1.2. Financial Performance
    • 11.5.1.3. Product Benchmarking
    • 11.5.1.4. Strategic Initiatives
  • 11.5.2. Diasorin S.P.A.
    • 11.5.2.1. Overview
    • 11.5.2.2. Financial Performance
    • 11.5.2.3. Product Benchmarking
    • 11.5.2.4. Strategic Initiatives
  • 11.5.3. Abbott
    • 11.5.3.1. Overview
    • 11.5.3.2. Financial Performance
    • 11.5.3.3. Product Benchmarking
    • 11.5.3.4. Strategic Initiatives
  • 11.5.4. QuidelOrtho Corporation
    • 11.5.4.1. Overview
    • 11.5.4.2. Financial Performance
    • 11.5.4.3. Product Benchmarking
    • 11.5.4.4. Strategic Initiatives
  • 11.5.5. Danaher Corporation
    • 11.5.5.1. Overview
    • 11.5.5.2. Financial Performance
    • 11.5.5.3. Product Benchmarking
    • 11.5.5.4. Strategic Initiatives
  • 11.5.6. Thermo Fisher Scientific Inc
    • 11.5.6.1. Overview
    • 11.5.6.2. Financial Performance
    • 11.5.6.3. Product Benchmarking
    • 11.5.6.4. Strategic Initiatives
  • 11.5.7. Biomerieux SA
    • 11.5.7.1. Overview
    • 11.5.7.2. Financial Performance
    • 11.5.7.3. Product Benchmarking
    • 11.5.7.4. Strategic Initiatives
  • 11.5.8. F. Hoffmann-La Roche Ltd.
    • 11.5.8.1. Overview
    • 11.5.8.2. Financial Performance
    • 11.5.8.3. Product Benchmarking
    • 11.5.8.4. Strategic Initiatives
  • 11.5.9. QIAGEN
    • 11.5.9.1. Overview
    • 11.5.9.2. Financial Performance
    • 11.5.9.3. Product Benchmarking
    • 11.5.9.4. Strategic Initiatives
  • 11.5.10. Seegene Inc.
    • 11.5.10.1. Overview
    • 11.5.10.2. Financial Performance
    • 11.5.10.3. Product Benchmarking
    • 11.5.10.4. Strategic Initiatives
  • 11.5.11. Bosch Healthcare Solutions GmbH.
    • 11.5.11.1. Overview
    • 11.5.11.2. Financial Performance
    • 11.5.11.3. Product Benchmarking
    • 11.5.11.4. Strategic Initiatives
  • 11.5.12. QuidelOrtho Corporation
    • 11.5.12.1. Overview
    • 11.5.12.2. Financial Performance
    • 11.5.12.3. Product Benchmarking
    • 11.5.12.4. Strategic Initiatives
  • 11.5.13. Hologic, Inc.
    • 11.5.13.1. Overview
    • 11.5.13.2. Financial Performance
    • 11.5.13.3. Product Benchmarking
    • 11.5.13.4. Strategic Initiatives
  • 11.5.14. Siemens Healthineers AG
    • 11.5.14.1. Overview
    • 11.5.14.2. Financial Performance
    • 11.5.14.3. Product Benchmarking
    • 11.5.14.4. Strategic Initiatives